Drug Discovery & DDS– category –
-
AusperBio Secures $120M Series C Funding to Advance Phase 3 for Chronic Hepatitis B ASO Therapy AHB-137 and Accelerate Au-HALO™ Platform’s HBV siRNA Development
BioSpace Global Overview AusperBio Therapeutics has successfully completed a $120 million Series C financing round to vigorously advance its lead antisense oligonucleotide (ASO) therapy, AHB-137, through Phase 3 enrollment and towards co... -
Biopharma M&A Intensifies Driven by Patent Cliffs and Pipeline Enhancement, Evolving Deal Structures with Increased CVRs
Endpoints News Global Overview Biopharma M&A activity is rapidly intensifying, spurred by the pressure of patent expirations and the necessity to fill pipeline gaps. Companies are accelerating acquisitions to secure new therapies and... -
Monod Bio Licenses AI-Designed Protein Technologies to SignalChem Biotech for Accelerated Custom Luminescent Assay Development
The Scientist Global Overview AI-driven protein design company Monod Bio has entered into a non-exclusive licensing agreement with SignalChem Biotech, enabling the integration of Monod Bio's LuxSit de novo luciferase technology and NovoB... -
Biohaven Secures Global Licensing Deal with SK Biopharmaceuticals for Kv7 Ion Channel Platform and Lead Epilepsy Candidate Opakalim, Including $400M Upfront
PR Newswire Global Overview Biohaven and SK Biopharmaceuticals have signed a strategic global licensing and co-development agreement for a novel Kv7 ion channel platform, including its lead candidate Opakalim for focal epilepsy. Under th... -
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for Global Development and Commercialization of Novel GLP-1-Independent Obesity Candidate HM17321
Pharmaceutical Executive Daily Global Overview Hanmi Pharm has signed an exclusive, global licensing agreement with Genentech, a Roche Group member, for the worldwide development, manufacturing, and commercialization of HM17321, a novel ... -
EMA’s CHMP Endorses Marketing Authorization Expansion for Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) for Childhood Obesity in Rare Genetic Disorders (Ages 2+)
Bio-Research.AI Europe Overview Rhythm Pharmaceuticals announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization expansion for IMCIVREE (setmelanoti... -
Piramal Pharma Acquires Additional 40.67% Stake in Yapan Bio; Curium Announces ~$8 Billion Acquisition of Lantheum
Pharmaceutical Technology Global Overview Indian pharmaceutical services group Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio, a Hyderabad-based CDMO specializing in vaccines and biopharmaceuticals, strengthening its... -
Biopharma M&A Surges in H1 2026, Led by Sun Pharma’s $11.75B Organon Acquisition and Merck KGaA’s $11.3B Bio-Techne Deal
Herbert Smith Freehills Kramer Global Overview The first half of 2026 witnessed a significant resurgence in pharmaceutical M&A activity, with several major acquisitions driving market consolidation. Notable transactions include Sun P... -
Caltech Unveils ‘BrainCAB’ Molecular Shuttle for Enhanced Blood-Brain Barrier Drug Delivery Targeting Carbonic Anhydrase IV
Caltech News USA Overview Caltech researchers have developed 'BrainCAB,' a novel molecular shuttle that efficiently crosses the blood-brain barrier (BBB) to deliver drugs to the brain. This technology utilizes a small molecule shuttle th... -
A*STAR Successfully Identifies Bispecific Antibody Stability Risks: Enhancing Manufacturability and Robustness of Next-Gen Biologics
A*STAR Singapore Overview Researchers at A*STAR's Bioprocessing Technology Institute (BTI) in Singapore have successfully identified 'labile regions' within bispecific antibodies (BsAbs) that compromise their manufacturing and stability....
